PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
PRINCETON, N.J. - Soligenix, Inc. (NASDAQ:SNGX) announced Thursday that its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet’s Disease has yielded positive ...
Investing.com -- Soligenix Inc (NASDAQ:SNGX) stock climbed 5.2% on Thursday after the company published promising results from its Phase 2a study of SGX945 for treating oral ulcers in Behçet’s Disease ...
A chronic inflammatory disease similar to canker sores that occur when fatigued, but which invades the eyes, genitals, and major organs, causing severe complications, is Behçet’s disease. It is named ...
A chronic inflammatory disease similar to canker sores that occur when fatigued, but which invades the eyes, genitals, and major organs, causing severe complications, is Behçet’s disease. It is named ...
The Orphan Drug designation was supported by data from an open-label phase 2 trial that included 8 adult patients with mild to moderate Behçet disease and active oral and/or genital ulcers. The Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback